Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 127

Sort by

Sort Order Select

Journal Articles

Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Naïve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)

Jennifer R. Brown, MD PhD, Matthew S. Davids, MD, Julie E Chang, MD, Shuo Ma, MD PhD, Juliana M L Biondo, MD, Yong Mun, PhD, Madlaina Breuleux, PhD, William G. Wierda, MD PhD

Blood (2019) 134 (Supplement_1): 4320.

https://doi.org/10.1182/blood-2019-123665

Published: 2019

Journal Articles

Incidence of High-Grade Hematologic Toxicities and Hypertension in Patients with Hematological Malignancies Treated with Ibrutinib

Chandler Graf, Anita Sultan, MD, Donald P. Quick, MD, Bradley J. Grant, JD, Sriman Swarup, MDMBBS, Thura Win Htut, MBBS, MRCP, Pwint Phyu Hlaing, MD, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Sanjay Awasthi, MD, Nicholas D'Cunha, MD, Lukman Tijani, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5876.

https://doi.org/10.1182/blood-2019-123297

Published: 2019

Journal Articles

Systematic Literature Review on Global Real-World Treatment Patterns of Mantle Cell Lymphoma (MCL)

Keri Keri Yang, Beth Lesher, PharmD, Eleanor Lucas, BA, Tony Caver, PhD, Boxiong Tang, MD PhD

Blood (2019) 134 (Supplement_1): 5881.

https://doi.org/10.1182/blood-2019-130896

Published: 2019

Journal Articles

Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

Christoph Kornauth, Charles Herbaux, MD MSc, Bernd Boidol, PhD, Chantal Guillemette, Patrick Caron, Stéphanie Poulain, MD PhD, Olivier Tournilhac, Marius E Mayerhoefer, Ulrich Jaeger, MD, Stefan Kubicek, Matthew S. Davids, MD, Philipp Bernhard Staber, MD PhD

Blood (2019) 134 (Supplement_1): 3965.

https://doi.org/10.1182/blood-2019-124392

Published: 2019

Journal Articles

Updated Meta-Analysis to Evaluate the Incidence of Atrial Fibrillation and Major Bleeding in Patients with Hematologic Malignancies Treated with Ibrutinib

Sriman Swarup, MDMBBS, Anita Sultan, MD, Lukman Tijani, MD, Thura Win Htut, MBBS, MRCP, Nicholas D'Cunha, MD, Sariya Wongsaengsak, MD, Donald P. Quick, MD, Khaing Khaing Htwe, Pwint Phyu Hlaing, MD, Myat Min Han, MD, Yin Mon Myat, MD, Akshar Dash, Fred Hardwicke, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 2200.

https://doi.org/10.1182/blood-2019-123261

Published: 2019

Journal Articles

Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!

Martin Dreyling, Wolfram Klapper, Simon Rule

Blood (2018) 132 (26): 2722–2729.

https://doi.org/10.1182/blood-2017-08-737502

Published: 2018

Journal Articles

Regulated Natural Killer Cell Expansion and Anti-Tumor Activity with Inducible MyD88/CD40

Xiaomei Wang, PhD, Wei-Chun Chang, PhD, Daniel L. Jasinski, PhD, Jan L. Medina, BS, Ming Zhang, BS, Aaron Foster, PhD, David M. Spencer, PhD, J. Henri Bayle, PhD

Blood (2018) 132 (Supplement 1): 4550.

https://doi.org/10.1182/blood-2018-99-120151

Published: 2018

Journal Articles

Differential Expression of Inducible Caspase-9 (iC9) in Allogeneic T Cells Allows Selective Depletion of Activated T Cells Following Exposure to Rimiducid and Permits In Vivo Allodepletion

Xiaoou Zhou, MD PhD, An Lu, Kelly L Sharp, Margie Harris, Madhavi Anumula, MS, J. Bayle, PhD, David M. Spencer, PhD, Aaron Foster, PhD, Joanne Shaw, PhD

Blood (2018) 132 (Supplement 1): 3496.

https://doi.org/10.1182/blood-2018-99-119285

Published: 2018

Journal Articles

Targeting Intracellular Signaling Cascades for Patients with Relapsed, Refractory Multiple Myeloma: A Systematic Review of Clinical Trials

Shehroz Aslam, MD, Mustafa Nadeem Malik, MD, Abdul Rafae, MD, Rida Riaz, MBBS, Seren Durer, MD, Ceren Durer, MD, Faisal Mahfooz, MD, Muhammad Jahanzeb Khalil, MD, Jemin Aby Jose, MD, Zunairah Shah, MBBS, Chaudhry Saad Sohail, MD, Maaz Ahmed Yusufi, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5659.

https://doi.org/10.1182/blood-2018-99-115721

Published: 2018

Journal Articles

Systematic Literature Review of the Cost-Effectiveness of Treatments, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma

Neerav Monga, Jamie Garside, Matthew S. Davids, MD, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Katherine Ward, Iain Fotheringham, Peter O'Donovan, Lori Parisi, Christoph Tapprich

Blood (2018) 132 (Supplement 1): 5848.

https://doi.org/10.1182/blood-2018-99-118385

Published: 2018

Journal Articles

Risk of Bleeding with Ibrutinib in Patients with B-Cell Malignancies: An Updated Meta-Analysis of Phase III Randomized Controlled Trials

Somedeb Ball, MD, Abhishek Maiti, MBBS, Meily Arevalo, MD, Avash Das, MBBS, Wasawat Vutthikraivit, Peggy J Edwards, AMLS, Fred Hardwicke, MD

Blood (2018) 132 (Supplement 1): 5553.

https://doi.org/10.1182/blood-2018-99-120161

Published: 2018

Journal Articles

Risk of Infection with Ibrutinib in Patients with B-Cell Malignancies: A Meta-Analysis of Phase III Randomized Controlled Trials

Somedeb Ball, MD, Wasawat Vutthikraivit, Avash Das, MBBS, Peggy J Edwards, AMLS, Fred Hardwicke, MD, Nicholas J Short, MD, Abhishek Maiti, MBBS

Blood (2018) 132 (Supplement 1): 2871.

https://doi.org/10.1182/blood-2018-99-113743

Published: 2018

Journal Articles

A Decade of Drug Development through Phase-1 Trials; Systematic Review of Literature for Novel Drugs and Targets in Multiple Myeloma

Imad Ud Deen, MBBS, Muhammad Umar Khalid, MD, Atlantis Dawn Russ, MD PhD, Anh Hua, BS, Ahmad Iftikhar, MD, Adeela Mushtaq, MD, Ahmad Safdar, BS, Ali McBride, PharmD,MS, Faiz Anwer, MD

Blood (2017) 130 (Supplement 1): 5399.

https://doi.org/10.1182/blood.V130.Suppl_1.5399.5399

Published: 2017

Journal Articles

Activation of Autophagy in Models of SF3B1 Mutant MDS

Blood (2017) 130 (Supplement 1): 4230.

https://doi.org/10.1182/blood.V130.Suppl_1.4230.4230

Published: 2017

Journal Articles

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

Disha Malani, MRes, Ashwini Kumar, MRes, Bhagwan Yadav, PhD, Mika Kontro, MD, Swapnil Potdar, MSc, Samuli Eldfors, MSc, Jani Saarela, Bjørn Tore Gjertsen, Riikka Karjalainen, Tero Aittokallio, Astrid Murumagi, Maija Wolf, PhD, Simon Anders, PhD, Krister Wennerberg, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD

Blood (2017) 130 (Supplement 1): 854.

https://doi.org/10.1182/blood.V130.Suppl_1.854.854

Published: 2017

Journal Articles

Comparative Effectiveness of Single-Agent Ibrutinib in the Ray Trial Versus Real-World Treatment in the Lyon-Sud Database in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Clementine Sarkozy, MD, Alexandra Traverse-Glehen, MD PhD, Emmanuel Bachy, Lionel Karlin, MD, Hervé Ghesquières, MD PhD, Hervé Besson, Ruben Hermans, Nollaig Healy, Jamie Garside, Joris Diels, Finlay MacDougall, Corinna Pick-Lauer, Gilles Salles, MD

Blood (2017) 130 (Supplement 1): 2770.

https://doi.org/10.1182/blood.V130.Suppl_1.2770.2770

Published: 2017

Journal Articles

A Phase II Study to Determine the Safety and Efficacy of the Dual m-TORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination with Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Toby A. Eyre, MBBChir, MRCP, Catherine Hildyard, MRCP, BA, Anesh Panchal, BSc, MSc, Aimee E Houlton, BSc, MSc, Louise Hopkins, BSc, MRes, Angela Hamblin, MD PhD, Kim Linton, MBChB PhD, Andrew Pettitt, FRCPath, PhD, Simon Rule, MD, Kate Cwynarski, PhD MD, Sally Barrington, MBBS, MSc, FRCP, FRCR, MD, David Wrench, MA, MBBChir, FRCPath, PhD, Andrew Davies, PhD, Graham Collins, MD PhD

Blood (2017) 130 (Supplement 1): 5210.

https://doi.org/10.1182/blood.V130.Suppl_1.5210.5210

Published: 2017

Journal Articles

Incidence of and Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib: Results from an Integrated Analysis

Blood (2017) 130 (Supplement 1): 1743.

https://doi.org/10.1182/blood.V130.Suppl_1.1743.1743

Published: 2017

Journal Articles

Temsirolimus in Combination with Three Different Immuno-Chemotherapy Regimens in Relapse and Refractory Mantle Cell Lymphoma, Final Results of the T 3 Phase IB Trial of the Lysa Group

Steven Le Gouill, MD PhD, Krimo Bouabdallah, MD, Barbara Burroni, MD, Thierry Lamy, MD PhD, Remy Gressin, MD, Guillaume Cartron, MD PhD, Catherine Thieblemont, MD PhD, Clémentine Sarkozy, MD, Corinne Haioun, MD PhD, Olivier Casasnovas, MD, Emmanuel Gyan, MD PhD, Olivier Hermine, MD PhD

Blood (2016) 128 (22): 2987.

https://doi.org/10.1182/blood.V128.22.2987.2987

Published: 2016

Journal Articles

Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309

Justin Kline, MD, Aaron P. Rapoport, MD, Adam M. Petrich, MD, Kenneth S. Cohen, MD, Sachdev P. Thomas, MD, Sreenivasa Nattam, MD, Krishna Rao, MD, Bethany Sleckman, MD, Walter Stadler, MD, Theodore Karrison, PhD, Sonali M. Smith, MD

Blood (2016) 128 (22): 4147.

https://doi.org/10.1182/blood.V128.22.4147.4147

Published: 2016

NARROW

Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Naïve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)

Incidence of High-Grade Hematologic Toxicities and Hypertension in Patients with Hematological Malignancies Treated with Ibrutinib

Systematic Literature Review on Global Real-World Treatment Patterns of Mantle Cell Lymphoma (MCL)

Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

Updated Meta-Analysis to Evaluate the Incidence of Atrial Fibrillation and Major Bleeding in Patients with Hematologic Malignancies Treated with Ibrutinib

Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!

Regulated Natural Killer Cell Expansion and Anti-Tumor Activity with Inducible MyD88/CD40

Differential Expression of Inducible Caspase-9 (iC9) in Allogeneic T Cells Allows Selective Depletion of Activated T Cells Following Exposure to Rimiducid and Permits In Vivo Allodepletion

Targeting Intracellular Signaling Cascades for Patients with Relapsed, Refractory Multiple Myeloma: A Systematic Review of Clinical Trials

Systematic Literature Review of the Cost-Effectiveness of Treatments, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma

Risk of Bleeding with Ibrutinib in Patients with B-Cell Malignancies: An Updated Meta-Analysis of Phase III Randomized Controlled Trials

Risk of Infection with Ibrutinib in Patients with B-Cell Malignancies: A Meta-Analysis of Phase III Randomized Controlled Trials

A Decade of Drug Development through Phase-1 Trials; Systematic Review of Literature for Novel Drugs and Targets in Multiple Myeloma

Activation of Autophagy in Models of SF3B1 Mutant MDS

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

Comparative Effectiveness of Single-Agent Ibrutinib in the Ray Trial Versus Real-World Treatment in the Lyon-Sud Database in Patients with Relapsed or Refractory Mantle Cell Lymphoma

A Phase II Study to Determine the Safety and Efficacy of the Dual m-TORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination with Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Incidence of and Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib: Results from an Integrated Analysis

Temsirolimus in Combination with Three Different Immuno-Chemotherapy Regimens in Relapse and Refractory Mantle Cell Lymphoma, Final Results of the T 3 Phase IB Trial of the Lysa Group

Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only